drugset

drugset / Trial / NCT04970355

Efficacy of Erenumab in Chronic Cluster Headache

NCT04970355 ↗

Phase 2 Completed 101 enrolled Charite University, Berlin, Germany

RandomizedParallel-groupDouble-blindPrevention

Summary

The main purpose of this study is to evaluate the efficacy of erenumab in participants with chronic cluster headache.

Timeline

Start: 2021-12-02
Primary completion: 2023-09-27
Completion: 2023-09-27

Outcome

Missed primary endpoint

paper The primary end point was not met over weeks 5 and 6 of the double-blind phase PMID 40526384 ↗

Publications

Mecklenburg J, Gaul C, Fitzek M, Overeem LH, Heinze A, Fleischmann R, Boeger A, Holle-Lee D, Straube A, Gendolla A, Israel-Willner H, Lorenz M, Gossrau G, Naegel S, Rimmele F, Rattan S, Materne B, Schulze D, Raffaelli B, Reuter U; CHERUB01 Study Group. Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial. JAMA Netw Open. 2025 Jun 2;8(6):e2516318. doi: 10.1001/jamanetworkopen.2025.16318.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	140 mg	Subcutaneous

Indications